Published in Cancer Weekly, April 7th, 2009
That's why James M. Golubieski, president of Foundation Venture Capital Group, LLC, a New Jersey Health Foundation affiliate, is proud to announce that the company has made a $500,000 commitment to Actinobac Biomed Inc., a company developing a therapeutic agent targeting white leukemic blood cells for the treatment of hematological malignancies, including leukemia, myeloma and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.